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Antrodia  cinnamomea  is a rare  and  endemic  medicinal  mushroom  native  to Taiwan.  The pharmacologi-
cal  effects  of  A. cinnamomea  have  been extensively  studied.  The  aim of the  present  study  was  to  assess
the  genotoxic,  oral  toxic  and  teratotoxic  effects  of  A. cinnamomea  health  food  product  “Leader  Deluxe
Antrodia  cinnamomea  (LDAC)”  using  in vitro  and  in  vivo  tests.  The  Ames  test  with  5 strains  of  Salmonella
typhimurium  showed  no signs  of increased  reverse  mutation  upon  exposure  to LDAC  up  to  concentration
of  5 mg/plate.  Exposure  of  Chinese  Hamster  Ovary  cells  (CHO-K1)  to  LDAC  did  not produce  an increase
in  the frequency  of  chromosomal  aberration  in vitro.  In addition,  LDAC  treatment  did not  affect  the  pro-
portions  of  immature  to  total erythrocytes  and  the  number  of micronuclei  in  the  immature  erythrocytesenotoxicity
utagenicity
hromosomal aberration
icronuclei
of  ICR  mice.  Moreover,  14-days  single-dose  acute  toxicity  and  90-days  repeated  oral  dose  toxicity  tests
with rats  showed  that  no observable  adverse  effects  were  found.  Furthermore,  after  treatment  with  LDAC
(700–2800 mg/kg/day)  there  was  no  evidence  of observable  segment  II reproductive  and  developmental
toxic  effects  in  pregnant  SD  rats  and  their  fetuses.  These  toxicological  assessments  support  the  safety  of
LDAC  for  human  consumption.
©  2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC. Introduction
Antrodia cinnamoea (AC) is a unique medicinal mushroom,
hich is rare and endemic to Taiwan. In traditional Chinese
edicine, this mushroom was used to treat various illnesses
ncluding food poisoning, drug intoxication, abdominal pain,
ypertension, diarrhea, skin irritation and liver and tumorigenic
iseases [2,8]. After being used as a traditional Chinese medicine,
C is now believed one of the most liver protecting natural
roducts in Taiwan. Recent studies have indicated that the phar-
acological application of this mushroom goes beyond traditional
nowledge [10]. An increasing number of studies support the con-
ention that AC possesses various pharmacological effects including
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ersity, 250-Kuo-Kung Road, Taichung-402, Taiwan. Fax: +886 4 22873628.
E-mail address: taiwanﬁr@dragon.nchu.edu.tw (S.-Y. Wang).
ttp://dx.doi.org/10.1016/j.toxrep.2015.10.007
214-7500/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
anti-oxidant, anti-inﬂammatory, anti-cancer, anti-metastatic, anti-
hyperlipemic, anti-diabetic, hepato-protective, neuro-protective,
cardio-protective and immunomodulatory effects [8,9,10,14]. The
potent pharmacological effects of AC have been attributed
to its high content of bioactive components such as ter-
pinoids, benzenoids, benzoquinone derivatives, maleic/succinic
acid derivatives, lignans, polysaccharides, sterols, nucleotides and
fatty acids [10,14]. Predominantly these bioactive compounds,
especially triterpinoids, are found in the fruiting bodies [8]. There-
fore, demand for the fruiting bodies of AC has far exceeded the
supply. However, to compensate the demand, researchers devel-
oped other techniques for the mass production such as wood or
solid-state cultivation and liquid or submerged cultivation.
Allied to these potential health beneﬁts, AC is widely used as
a health food supplement in Taiwan and available in the form
of powder, tablet and capsules. To this end, the safety issues of
AC must be examined. Previous studies have indicated that AC
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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Table 1
Chemical substances and concentrations used as positive controls for Ames test
Strain Without S9 mix  With S9 mix  Chemical
Substance Dose (g/plate) Chemical substance Dose (g/plate)
TA98 2-Nitroﬂuorene 1 2-Aminoanthracene 1
TA100 Sodium azide 1 Benzo(a) pyrene 1
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TTA102 Mitocin C 0.2 
TA1535 Sodium azide 1 
TA1537 9-Aminoacridine 50 
roducts are of low oral toxicity, with an oral medial lethal dose
LD50) >1.5 g/kg body weight in CD mice [3]. Although hundreds
f AC products are sold, only three products have been awarded
 “National Health Food” certiﬁcation by Taiwan’s Department of
ealth. For this study, we selected one certiﬁcated AC product,
eader Deluxe Antrodia cinnamomea (LDAC), as study material. To
ssess the safety of LDAC, the present study performs genotoxicity,
ral toxicity and teratogenicity assessments of LDAC.
Genotoxicity studies of herbal products are of great interest
ecause of the widespread and long- term use of herbal remedies,
s well as health food supplements [11]. Many herbal products con-
ain compounds known to cause severe side effects or even death
n animals and humans. In addition, many natural products have
een reported to act as a mutagens and/or carcinogens. A vari-
ty of in vitro genotoxicity test systems were developed including
he bacterial reverse mutation test (Ames test), cultured mam-
alian cell systems such as Chinese hamster ovary (CHO) cells or
uman peripheral blood lymphocytes (PBL). The in vivo rodent bone
arrow erythrocyte micronucleus test is the most widely used
hort-term test to identify the genotoxic effects of test samples such
s chromosomal abberation and aneuploidy.
In the present study, the mutagenic potential of LDAC was eval-
ated by a bacterial reverse mutation assay, while genotoxicity
as examined by a mammalian chromosomal aberration test and
ammalian erythrocyte micronuclei test using CHO-K1 cells and
at bone marrow erythrocytes, respectively. Acute and repeated
ose oral toxicity studies were performed with rats. The reproduc-
ive and developmental assessment was carried out using pregnant
emale rats.
. Materials and methods
.1. Test substance
The health food supplement LDAC was manufactured by Taiwan
eader Biotech Corp, Taipei City, Taiwan. LDAC powder conists of
% extract of fruiting bodies from cut-log cultivation, 94% mycelium
rom high-efﬁcient solid state cultivation of A. cinnamomea and 1%
agnesium stearate.
.2. Chemicals
Ham’s F-12 medium, heat inactivated fetal bovine serum
FBS), l-Glutamine, Penicillin and Streptomycin were obtained
rom Biological Industries Israel Beit-Haemek Ltd., Israel. Mit-
mycin C, benzo(a) pyrene, 2- Nitroﬂuorene, sodium azide, 9-
minoanthracene, histidine, biotin, Giemsa stain, acridine orange,
yclophosphamide and Methylthiazolyldiphenyl-tetrazolium bro-
ide (MTT) were purchased from Sigma–Aldrich, St. Louis, MO.
olcemid was obtained from Life Technologies, Carlsbad, CA..3. Bacterial reverse mutation test (Ames test)
The histidine-requiring Salmonella typhimurium strains TA98,
A100, TA102, TA1535 and TA1537 were obtained from Molecular2-Aminoanthracene 5
2-Aminoanthracene 5
2-Aminoanthracene 5
Toxicology Inc., Bonne, NC. The genotypes of the bacterial strains
were conﬁrmed by histidine mutation, rfa mutation, uvrB repair
and ampicillin resistance before the assay.
Prior to the assay, a dose range ﬁnding test was performed with
LDAC (0.313–5 mg/plate) in the TA100 strain. A plate incorporation
assay was  employed and performed to detect reverse mutation in
bacterial strains [1]. Brieﬂy, 0.05 mL  of aqueous solution of LDAC
(0313, 0.625, 1.25, 2.5 and 5 mg/plate) was mixed with 0.1 mL  of
overnight culture of S. typhimurium strains (2 × 109 cells/mL) in
either 0.5 mL  of 0.2 M phosphate buffer (without S9 metabolic acti-
vation group) or 0.5 mL  S9 mixture (S9 metabolic activation group).
The composition of S9 mixture was 5% v/v Aroclor-1254 induced SD
rat liver S9 (Molecular Toxicology Inc) and 0.15 M KCl. The mixture
was subsequently mixed with 2 mL  of molten top agar solution with
0.5 mM histidine/biotin. The cultures were incubated at 50 ± 1 ◦C
before transferring to minimal glucose agar plates. The solidiﬁed
agar plates were inverted and incubated at 37 ± 1 ◦C for 48–72 h.
Then the colonies were counted. Double distilled water was served
as negative control, whereas for positive controls, test substance
and corresponding concentrations were summarized in Table. 1.
2.4. Mammalian chromosomal aberration test
For the in vitro chromosomal aberration test, the Chinese ham-
ster ovary cell line (CHO-K1) was  obtained from the Bioresource
Collection and Research Center (BCRC, Hsinchu, Taiwan). CHO-K1
cells were cultured in Ham F-12 medium supplemented with 10%
heat inactivated FBS, 2 mM L-Glutamine and 100 U/L Penicillin
and Streptomycin in a humidiﬁed atmosphere containing 5% CO2
at 37 ± 1 ◦C. LDAC was  dissolved in the culture media at a con-
centration of 10 mg/mL, and then centrifuged at 1200 g for 5 min.
The supernatant was  ﬁltered through a 0.22 m ﬁlter and used
for subsequent studies. 5 mg/mL  was used as the highest dose for
cytotoxicity assay. The other testing doses were serial dilutions of
5 mg/mL  to give 0.313, 0.625, 1.25, 2.5 and 5 mg/mL. Plain culture
media served as the negative control, and the positive controls were
0.5 g/mL mitomycin C for the group without S9 and 25 g/mL
benzo(a) pyrene for the S9 group.
CHO-K1 cells at a density of 4 × 105 cells/well were seeded in 6-
well culture plates and incubated for 24 h before treatment. LDAC
and controls were administered in three test systems. For short-
term treatment, test samples were exposed for 3 h followed by a
recovery period of 6 h. For metabolic activation, test samples were
exposed with S9 for 3 h. For long-exposure, the test samples were
kept in culture for 22 h without S9. After the designated treatment
duration, cytotoxicity was  determined by MTT  assay using an ELISA
microplate reader (-Quant, Bio-Tek Instruments Inc., Winooski,
VT). The morphology of the cells was observed and recorded by
microscope at 100 × magniﬁcation. In parallel, specimens were pre-
pared for the chromosomal aberration test. In brief, 100 ng/mL of
Colcemid solution was added to the culture and incubated for 2 h.
Cells were harvested, treated with a hypotonic solution (0.75 mM
KCl) and ﬁxed with a mixture of ice-cold methanol/glacial acetic
acid at a ratio of 3:1 v/v. Cell smear on clean glass slides were
air-dried and stained with Giemsa solution.
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The frequency of the cells with chromosome structural aberra-
ion was scored in 200 well-spread metaphase cells with a number
f centromeres equal to the model number (20 ± 2) scored for each
ose in duplicate. The structural chromosome aberrations were
lassiﬁed into 5 groups: chromosome breakage (csb), chromosome
xchange (cse), chromatid breakage (ctb), chromatid exchange
cte), and other abnormalities such as polyploidy, these were scored
nd recorded by photographing.
.5. Animals
Seven week old male and female ICR mice and 6–8 week old
ale and female Sprague-Dawley CD (SD) IGS rats were obtained
rom BioLasco Taiwan Co. Ltd, Taipei, Taiwan. Animals were housed
n pathogen-free cages (5–6 mice/cage and 2 rats/cage of the same
ender) in the Association for Assessment and Accreditation of Lab-
ratory Animal Care (AAALAC) accredited facility of Level Biotech.
nc., Taipei, Taiwan. The temperature was set at 21 ± 2 ◦C, rela-
ive humidity 55 ± 20%, and lighting was 12 h per day. Autoclaved
everse osmosis (RO) treated water was supplied ad libitum and
aboratory rodent diet (LabDiet, PMI  Nutation International, Rich-
ond, IN) supplied for all animals. The bedding was composed
f coarse grade Aspen Chip (Northeastern Products Corp, Warrens
urg, NY) and was changed weekly.
.6. Mammalian micronucleus test
The micronucleus test was performed following the Orga-
ization for Economic Cooperation and Development (OECD)
uidelines. Positive control group mice were administered
0 mg/kg cyclophosphamide via intraperitoneal injection (using a
0 mg/mL  solution dosed at 8 mL/kg b.w); the test sample groups
eceived LDAC orally at 700, 1400 or 2800 mg/kg (using 70, 140
nd 280 mg/mL  in water and dosed at 10 mL/kg b.w) and a neg-
tive control group received sterile water at 10 mL/kg. All doses
ere administered using a stainless steel feeding needle. Mice
ere monitored daily for any post-treatment clinical symptoms,
nd their body weight was noted before and after treatment. 48-
nd 72 h post-treatment, peripheral blood samples (2–3 L) were
btained from the tail vein and smeared on acridine orange coated
icroscopic slides. The smeared slides were incubated at room
emperature for 2–3 h prior to microscopic examination. A ﬂuores-
ence microscope (Carl Zeiss Microscopy GmbH, Jena, Germany)
ith 488 nm excitation and 515 nm long pass ﬁlter was used for
olychromatic erythrocytes and micronucleus identiﬁcation and
ounting. The percentage of polychromatic erythrocytes (PCE) in
000 erythrocytes was quantiﬁed. At least 2000 PCE/animal were
cored for the incidence of PCE with micronucleus (MN  ‰PCE).
.7. Acute oral toxicity study
An acute oral toxicity (14 day) study was performed to exam-
ne the possible adverse effects of the test sample LDAC in rats via
ral administration. After acclimatization for 6 days, 48 rats were
ivided into 4 groups (Group I–IV) 12 in each group of 6 male and
 female rats. Group 1 served as a control group received sterile
ater (Taiyu Chemicals & Pharmaceuticals Co Ltd, Hsinchu, Taiwan)
ia oral gavage in a volume of 10 mL/kg b.w, whereas Group II–IV
eceived 1400, 2800 and 5600 mg/kg b.w LDAC in water solution
espectively in a volume of 10 mL/kg b.w. These doses were 25, 50
nd 100 times the human recommended daily intake based on a
ody weight conversion basis. All animals were fasted overnight
16 h) prior to dosing. The animals in each group were dosed twice
n Day 1 with the control or LDAC. The second dose was  performed
ithin 6 h of the ﬁrst. The dosing day was denoted as study day 1
Day 1). On Day 1, the animal feed was re-supplied after the secondrts 2 (2015) 1409–1417 1411
dose. Mortality and moribundity were recorded every 12 h inter-
val. All rats were observed individually for any clinical signs at 0–4 h
after dosing on Day 1, thereafter once daily during the study period.
Any abnormal ﬁndings, local/systemic and behavioral abnormali-
ties were recorded and documented. The body weight of each rat
was recorded prior to dosing and at 4, 8 and 15 days post dosing.
Animals were sacriﬁced with overdose of CO2 on Day 15. The gross
necropsy performed included examination of the external surfaces,
the thoracic and abdominal cavities, including the intestine as the
dosing site.
2.8. Repeated dose 90-day oral toxicity study
A repeated dose toxicity (90 days) study was conducted to
evaluate the possible health hazards likely to arise from repeated
exposure of LDAC in rats via oral administration in accordance with
OECD guidelines. After acclimatization for a week, 96 rats were
divided into 4 groups (Group I–IV), 24 in each group of 12 male and
12 female rats. Group I served as a control group and received sterile
water at a volume of 10 mL/kg b.w, whereas Groups II–IV were sam-
ple treatment groups and received 700, 1400 and 2800 mg/kg b.w,
respectively in a volume of 10 mL/kg b.w in water. All animals in
each group were dosed once a day for 90 days and they were mon-
itored daily in the same manner as described in the acute toxicity
study to observe signs of toxicity.
Ophthalmologic examination was performed for all animals
before treatment commenced and before terminal sacriﬁce. Cornea,
conjunctiva, anterior chamber, iris, and lens were examined by
an ophthalmoscope. Vaginal smear was examined once for each
female before necropsy.
Clinical pathology examinations including hematology, serum
chemistry and urine analysis were performed for all surviving ani-
mals after the 90-day dosing period. On the necropsy day, blood
samples were obtained from the abdominal aorta and collected into
three tubes: (1) containing K2 EDTA for complete blood count anal-
ysis; (2) containing sodium citrate for coagulation factor analysis;
and (3) without anti-coagulant for serum chemistry analysis. Urine
samples were collected approximately 12–16 h using metabolism
cages prior to terminal sacriﬁce. Animals were received water and
food while in metabolic cages.
Immediately after blood collection, all rats were sacriﬁced using
a ketamine (80 mg/mL) and Xylazine (8 mg/mL) anesthesia mix-
ture. The gross necropsies included examination of the external
surface of the body, all thoracic and abdominal cavities, intestines
and visceral organs. Tissue/organ samples were ﬁxed and preserved
in 10% neutral buffered formalin. Histopathological examinations
were performed only in the control (Group I) and the highest dose
group (Group IV). The formalin ﬁxed tissues were trimmed, embed-
ded, sectioned and stained with hematoxylin and eosin (H&E)
before microscopic examination.
2.9. Oral reproductive and developmental toxicity study
A reproductive and developmental toxicity study was con-
ducted in accordance with the “Safety Evaluation Method for Health
Food” by Department of Health, Taiwan. Sixty male virgin CD (SD)
IGS rats and 120 female virgin rats were purchased from Bio-
Lasco, Taiwan. Animals were individually identiﬁed by ear notch.
After acclimatization for a week, individual breeding pairs were
co-habited overnight in a suspended stainless steel cage. Notably,
in ﬁrst set, 60 male rats were co-habited with 60 female rats and
the second set, the same 60 male rats were again co-habited with
another 60 female rats. After mating, the female rats were trans-
ferred to polycarbonate cages. The mating was  conﬁrmed with
vaginal sperm and/or vaginal copulation plug [7] and was  desig-
nated as gestation day 0 (G 0). Conﬁrmed-mated females were
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ssigned to the four study groups. Eighty conﬁrmed pregnant
emale rats were divided into 4 groups (Group I–IV) 20 rats in each
roup at least. Group 1 served as a control group received ster-
le water in a volume of 10 mL/kg b.w, whereas Group II–IV were
DAC treated groups and received 700, 1400 and 2800 mg/kg b.w,
espectively in a volume of 10 mL/kg b.w in water during the major
mbryonic organogenesis period (G6–G15).
The maternal mortality and moribundity were observed twice
 day for 20 days. Clinical observations including changes in skin,
ur, eyes, mucous membranes, occurrence of secretions and excre-
ions, autonomic activity were recorded. Behavioral observations
uch as changes in gait, posture to response to handling as well
s the presence of colonic and tonic movements, stereotypies (e.g.,
xcessive grooming and repetitive circling), difﬁcult or prolonged
arturition or bizarre behavior (e.g., self- mutilation and walking
ackward) were noted. During the gestation period, all the animals
ere weighed on G0, G3, G6, G9, G12, G15, G18 and G20. Feeding
nd water consumption was monitored during study period. On
20, rats were euthanized by CO2 inhalation followed by exsan-
uination and immediately subjected to a laparohysterectomy.
ecropsy including examination of external surface of the body, all
riﬁces, thoracic, abdominal and cranial cavities and their content.
nternally, the skin was reﬂected from a ventral midline incision to
xamine mammary tissue and locate any subcutaneous masses. The
terus was excised and gravid uterine weight was recorded. Begin-
ing at the distal end of the right uterine horn, extending caudally
cross the cervix to the left uterine horn, position of the cervix, and
he number of total implantations were recorded. Each litter was
ategorized according to the known criteria such as viable fetus,
on-viable fetus, late resorption, early resorption, corpora luteal
ount and gravid uterus weight.
Following caesarean section, fetuses were examined for via-
ility. All surviving fetuses were individually weighed, sexed and
xamined external malformations and variations. Crown-rump
ength (mm)  of each fetus was recorded. After the external exam-
nation, each fetus was euthanized via intraperitoneal injection
f sodium pentobarbital and alternately assigned by number and
osition for either visceral or skeletal examination. Approximately
ne-half of the fetuses in each litter were placed in Bouin’s solu-
ion for a week for skull and visceral examination. All fetuses
xed in Bouin’s solution were subjected for soft tissue defects
sing the modiﬁed Wilson razor-blade technique for any internal
rgan abnormalities. Prior to skeletal staining, all fetuses assigned
or skeletal examination were eviscerated according to standard
ethod following preservation in 95% ethyl alcohol ﬁxative. The
viscerated skeleton was macerated with potassium hydroxide,
tained with Alizarin Red S and Alcian Blue, and cleared with glyc-
rin for subsequent skeletal studies. The skeleton of each fetus were
xamined for completeness of bone ossiﬁcation and malformations
r variations in the skeleton.
.10. Statistical analysis
All data obtained in this study were expressed in mean ± S.D. The
icronucleus frequency and chromosomal aberration test were
nalyzed by the model of Poisson distribution. The P value less than
.05 (P < 0.05) was considered statistically signiﬁcant. Ames test,
cute toxicity, repeated oral dose toxicity and reproductive and
evelopmental toxicity tests were analyzed by One-Way ANOVA
nd Dunnett’s tests by SPSS ver 12.0 software (IBM, Armonk, NY).
eterogenous data were analyzed with the Kruskal–Wallis non-
arametric ANOVA method. Probability of 0.05 (p < 0.05) was used
s the signiﬁcance criterion.rts 2 (2015) 1409–1417
3. Results and discussion
3.1. Bacterial reverse mutation test
Initially we validated the genotypes of ﬁve S. typhimurium
bacterial strains (TA98, TA100, TA102, TA1535 and TA1537) includ-
ing histidine mutation, rfa mutation and uvrB repair (Table. 2).
TA98 and TA100 possessed all endogenous characteristics, whereas
TA102 had no mutation on uvrB (uvrB). TA1535 and TA1537
contained no plasmid that rendered ampicillin and tetracycline
resistance, which were all consistent with previous reports [5,15].
Next, the cytotoxicity and range ﬁnding study suggest that the
LDAC is not toxic to the bacterial strain TA100 at dose of 0.313 to
5 mg/plate (Table S1). Thus, we set these doses 0.313, 0.625, 1.25,
2.5 and 5 mg/plate are test doses and performed Ames test with
ﬁve bacterial strains. As shown in Table 3, compared to the nega-
tive control groups (sterile water), the positive control substances
induced generally at least 3-fold increase of the number of reverse
mutation colonies, conﬁrming the validity of the test. The mean
number of revertant colonies of the negative control was within
the historical range. Moreover, we  found that LDAC did not increase
the mean number of reverse mutation at dose levels between 0.313
and 5 mg/plate in both normal and metabolically activated bacterial
strains (Table 3). These results suggest that LDAC does not induce
bacterial reverse mutation within the test doses.
3.2. Mammalian chromosome aberration test
A. cinnamomea has been reported to be a potent anti-tumor
agent [10]. Most of the antitumor agents are known to interact
with speciﬁc biological molecules. Previous studies have reported
that treatment with anti-tumor agents from different categories
induce free radicals in non-tumor cells in both in vitro and in vivo
[12]. Extracts of A. cinnamomea or its derived compounds induce
apoptosis in cancer cells through reactive oxygen species (ROS)
generation following DNA damage [6,13]. Thus, prior to the in vitro
assay, the cytotoxic effect of LDAC on CHO-K1 cells was  exam-
ined by MTT  assay. According to the results of MTT  assay (Table
S2), the cell viability was  markedly decreased at the highest
dose of LDAC (5 mg/mL). After exposure of CHO-K1 cells to LDAC
for 3 h in the absence of S9 metabolic activation, the viability
of was  decreased to 94.71 ± 1.70%, 83.49 ± 2.81%, 89.76 ± 2.84%,
83.57 ± 1.99% and 39.96 ± 4.55% by 0.313, 0.625, 1.25, 2.5 and
5 mg/mL  LDAC, respectively. The positive control mitomycin C
(0.5 g/mL) showed 95.78 ± 1.44% of cell viability after 3 h in the
absence of S9 metabolic activation. In addition, exposure of CHO-K1
cells to LDAC for 3 h in the presence of S9 metabolic activation, the
cell viability of LDAC was  found as 124.22 ± 1.74%, 111.86 ± 2.25%,
90.20 ± 7.90%, 79.54 ± 4.04% and 58.70 ± 8.88%by 0.313, 0.625, 1.25,
2.5 and 5 mg/mL. The positive control benzo(a) pyrene at 25 g/mL
showed 86.19 ± 4.82% of cell viability after 3 h in the presence
of S9. Moreover, exposure of CHO-K1 cells to LDAC for 18 h in
the absence of S9 metabolic activation cell viability was  recorded
as 81.76 ± 5.94%, 83.53 ± 5.37%, 63.10 ± 4.50%, 48.62 ± 4.07% and
27.36 ± 1.29% by 0.313, 0.625, 1.25, 2.5 and 5 mg/mL. After 18 h
exposure of mitomycin (0.5 g/mL) without S9 mixture showed
94.18 ± 4.15% of cell viability. Based on the results of the viability
test, dosages with over 50% cell viability, selected for use in the
chromosome aberration test were 0.625, 1.25 and 2.5 mg/mL  for
3 h treatment group without S9 and those used in the 3 h treatment
group with S9 were 1.25, 2.5 and 5 mg/mL. In the 18 h treatment
group without S9, the doses used in the chromosome aberration
test were 0.313, 0.625 and 1.25 mg/mL.
The result of the chromosome aberration test are summarized in
Table 4. The number of cells with chromosome aberration observed
in the negative control group under different test schemes were
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Table  2
Genotyping of the test of Solmonella typhimurium bacterial strains.
Histidine requirement uvrB rfa Ampicillin Tetracycline Spontaneous
Strains His+ Bio+ plate His- Bio+ plate Mutation Mutation Resistance Resistance Revertants
TA98 + – – + + – 34.7 ± 4.0
TA100 + – – + + – 142.0 ± 12.1
TA102  + – + + + + 318.0 ± 18.3
TA1535 + – – + – – 14.0 ± 2.0
TA1537 + – – + – – 14.3 ± 4.2
Table 3
Results of bacterial reverse mutation test.
Group Number of revertants/plate (without S9 activator) Number of revertants/plate (without S9 activator)
(mg/plate) TA98 TA100 TA102 TA1535 TA1537 TA98 TA100 TA102 TA1535 TA1537
Negative 34.7 ± 5.0 173.0 ± 8.7 334.0 ± 24.0 8.3 ± 1.2 11.3 ± 4.0 34.0 ± 4.4 141.7 ± 18.1 377.3 ± 26.0 10.7 ± 3.1 22.3 ± 1.2
Positive 224.7 ± 40.6* 624.7 ± 2.0* 1376.0 ± 144.2* 402.7 ± 48.4* 96.3 ± 16.2* 565.3 ± 53.3* 610.7 ± 90.7* 840.0 ± 28.8* 150.3 ± 9.8* 616.0 ± 63.5*
LDAC 5  37.3 ± 1.5 165. ± 33.2 282.7 ± 36.3 9.3 ± 3.2 6.0 ± 3.0 22.7 ± 4.9 102.7 ± 14.6 348.7 ± 15.1 8.3 ± 1.5 17.3 ± 0.6
2.5  37.7 ± 0.6 136.7 ± 9.7 260.7 ± 34.0 10.0 ± 3.0 12.3 ± 0.6 21.0 ± 4.4 115.0 ± 5.7 307.0 ± 49.5 10.0 ± 2.0 15.7 ± 1.2
1.25  36.0 ± 5.2 141.7 ± 21.6 364.0 ± 24.0 11.0 ± 3.5 14.7 ± 2.9 31.7 ± 7.6 118.0 ± 8.5 356.7 ± 58.5 11.7 ± 3.2 23.3 ± 2.9
0.625 38.7 ± 9.5 168.3 ± 16.0 344.7 ± 45.0 9.7 ± 1.5 16.7 ± 5.0 36.7 ± 7.4 124.3 ± 8.6 368.0 ± 8.5 12.0 ± 4.0 19.7 ± 6.7
0.313 39.7 ± 12.7 188.0 ± 19.5 341.3 ± 54.9 15.0 ± 1.4 16.3 ± 4.2 29.7 ± 1.6 140.0 ± 26.6 382.7 ± 30.3 9.3 ± 0.6 21.7 ± 2.5
All values presented as mean ± S.D. *Signiﬁcantly different compared to all dose of test compounds.
Table 4
Effect of LDAC on mammalian chromosome aberration in cultured CHO-K1 cells.
Treatment period Metabolic Test sample Aberration frequencya p valueb
Short-term treatment
(3 h)
Without S9 Negative control 1/200 –
Mitomicin C (0.5 g/mL) 20/200 0.0000*
LDAC (0.625 mg/mL) 1/200 0.7358
LDAC (1.25 mg/mL) 3/200 0.1991
LDAC (2.5 mg/mL) 3/200 0.1991
With  S9 Negative control 3/200 –
Benzo(a) pyrene (25 g/mL) 15/200 0.0002*
LDAC (1.25 mg/mL) 3/200 0.6472
LDAC (2.5 mg/mL) 3/200 0.6472
LDAC (5 mg/mL) 3/200 0.6472
Long  term treatment
(18 h)
Without
S9
Negative control 3/200 –
Mitomicin C (0.5 g/mL) 29/200 0.0000*
LDAC (0.313 mg/mL) 4/200 0.4335
LDAC (0.625 mg/mL) 3/200 0.6472
LDAC (1.25 mg/mL) 2/200 0.8571
a The aberration frequency was displayed in the manner of number of cells with chromosome aberration in 200 observed metaphase cells (n/200).
b The statistical analysis was  performed by Poisson distribution in comparison with negative control. The “*” represents the statistical signiﬁcance (p < 0.05)
Table 5
Effect of LDAC on percentage of PCE in erythrocytes and micronucleus frequency in PCE.
PCE% (mean ± S.D, n = 5–6) MN‰PCE (mean ± S.D, n = 5–6)
Treatment group Female Male Female Male
48 h 72 h 48 h 72 h 48 h 72 h 48 h 72 h
Neg. control (sterile water) 3.23 ± 0.36 3.3 ± 0.14 3.67 ± 0.36 3.53 ± 0.41 0.17 ± 0.26 0.42 ± 0.38 0.67 ± 0.68 0.50 ± 0.63
Cyclop. (80 mg/kg b.w) 0.6 ± 0.34* - ± - 1.02 ± 0.19* - ± - 23.80 ± 12.09* - ± - 28.80 ± 5.62* - ± -
3.7
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cLDAC  (700 mg/kg b.w) 3.44 ± 0.33 3.3 ± 0.25 4.04 ± 0.38 
LDAC  (1400 mg/kg b.w) 3.22 ± 0.08 3.42 ± 0.28 3.52 ± 0.29 
LDAC  (2800 mg/kg b.w) 3.7 ± 0.51 3.32 ± 0.18 3.72 ± 0.33 
ithin the historical data of this laboratory. The number of cells
ith chromosome aberration in 200 observed metaphase cells in
he positive control, mitomicin C (0.5 g/mL), was  20, 15, and 29
nder the three test Schemes 3 h without S9, 3 h with S9 and
8 h without S9, respectively, which was signiﬁcantly (p < 0.05)
ncreased compared to that of the negative controls. The chromo-
ome aberrations in LDAC treated cells were 1, 3 and 3 at 0.625,
.25 and 2.5 mg/mL  under 3 h without S9 and 3, 3 and 3 at 1.25, 2.5
nd 5 mg/mL, respectively under 3 h with S9 metabolic activation.
oreover, the chromosome aberration in 200 observed metaphase
ells were 4, 3 and 2 by 0.313, 0.625 and 1.25 mg/mL  LDAC, respec-6 ± 0.21 0.40 ± 0.42 0.40 ± 0.42 0.10 ± 0.22 0.40 ± 0.42
4 ± 0.17 0.30 ± 0.45 0.50 ± 0.50 0.40 ± 0.42 0.50 ± 0.50
8 ± 0.19 0.40 ± 0.42 0.30 ± 0.45 0.30 ± 0.45 0.20 ± 0.27
tively under 18 h without S9 metabolic activation. In summary, data
indicate that exposure to LDAC does not signiﬁcantly induce chro-
mosome aberration in cultured mammalian somatic cells under the
test conditions.
3.3. Mammalian micronucleus testBesides the possible use of LDAC as a health food supplement,
knowledge about its genotoxic potential is also of interest from
the point of human consumption. Therefore, next we  examined
whether treatment with LDAC resulted in chromosome damage
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Table 6
Effect of repeated oral dose (90 days) of LDAC on rats: Clinical observation.
Incidence during study period (n’/n’)1
Male Female
Clinical sign Study period Control(WFI) LDAC (mg/kg b.w) Study period Control(WFI) LDAC (mg/kg b.w)
700 1400 2800 700 1400 2800
Wound Day 27–30 1/12 0/12 0/12 0/12 Day 1–12 0/12 0/12 0/12 0/12
Day  31–41 0/12 0/12 0/12 0/12 Day 13–18 0/12 0/12 0/12 1/12
Day  42–43 1/12 0/12 0/12 0/12 Day 19–22 0/12 0/12 0/12 1/12
Day  44–57 0/12 0/12 0/12 0/12 Day 23–24 0/12 0/12 0/12 1/12
Day  58–63 0/12 0/12 0/12 0/12 Day 25–36 0/12 0/12 0/12 0/12
Day  64–75 0/12 0/12 0/12 0/12 Day 37–50 0/12 0/12 0/12 0/12
Day  76–81 0/12 0/12 0/12 0/12 Day 51–80 0/12 0/12 0/12 0/12
Day  82–84 0/12 0/12 0/12 0/12 Day 81–92 0/12 0/12 0/12 0/12
Day  85–92 0/12 0/12 0/12 0/12
Total incidence (n/n)2 0/12 0/12 0/12 0/12 Total incidence (n/n)2 0/12 0/12 0/12 1/12
Hair  loss Day 27–30 0/12 0/12 0/12 0/12 Day 1–12 0/12 0/12 0/12 0/12
Day  31–41 1/12 0/12 0/12 0/12 Day 13–18 0/12 0/12 0/12 0/12
Day  42–43 1/12 0/12 0/12 0/12 Day 19–22 0/12 0/12 0/12 0/12
Day  44–57 1/12 0/12 0/12 0/12 Day 23–24 0/12 0/12 0/12 0/12
Day  58–63 1/12 0/12 0/12 0/12 Day 25–36 0/12 0/12 0/12 0/12
Day  64–75 0/12 0/12 0/12 0/12 Day 37–50 0/12 0/12 0/12 0/12
Day  76–81 1/12 0/12 0/12 0/12 Day 51–80 0/12 0/12 0/12 0/12
Day  82–84 1/12 0/12 0/12 0/12 Day 81–92 0/12 1/12 0/12 2/12
Day  85–92 1/12 0/12 0/12 0/12
Total incidence (n/n)2 1/12 0/12 0/12 0/12 Total incidence (n/n)2 0/12 0/12 0/12 2/12
1n’/n’: Number of animals with observable sign/Number of animals alive.
2n/n: Total number of animals with observable sign/Total number of animals examined.
Table 7
Effect of repeated oral dose (90 days) of LDAC on rats: Hematological ﬁndings.
Hematology (Mean ± S.D, n = 12)
Parameters Male Female
LDAC (mg/kg b.w) LDAC (mg/kg b.w)
Control 700 1400 2800 Control 700 1400 2800
WBC  (103/L) 9.45 ± 2.28 9.34 ± 1.80 8.63 ± 1.56 10.25 ± 2.02 11.09 ± 14.14 8.19 ± 2.74 7.04 ± 1.87 6.89 ± 1.79
RBC  (106/L) 9.22 ± 0.41 9.33 ± 0.33 8.98 ± 0.43 9.12 ± 0.51 8.42 ± 0.44 8.34 ± 0.31 8.20 ± 0.31 8.27 ± 0.38
HGB  (g/dL) 16.33 ± 0.56 16.43 ± 0.41 15.991 ± 0.59 15.98 ± 0.72 15.78 ± 061 15.48 ± 0.42 15.48 ± 0.43 15.29 ± 0.50
HCT  (%) 45.08 ± 1.49 45.23 ± 1.10 44.03 ± 1.52 44.25 ± 1.95 43.69 ± 1.30 43.16 ± 1.40 43.17 ± 1.45 42.33 ± 1.24*
MCV  (fL) 48.91 ± 1.81 48.52 ± 1.30 49.05 ± 2.03 48.58 ± 2.45 51.93 ± 2.07 51.73 ± 1.26 52.61 ± 1.04 51.23 ± 1.54
MCH  (pg) 17.71 ± 0.48 17.62 ± 0.35 17.72 ± 0.54 17.53 ± 0.71 18.73 ± 0.53 18.57 ± 0.37 18.87 ± 0.39 18.51 ± 0.45
MCHC  (g/dL) 36.19 ± 0.49 36.31 ± 0.38 36.13 ± 0.55 36.13 ± 0.52 36.13 ± 0.67 35.88 ± 0.41 35.87 ± 0.44 36.12 ± 0.53
PLT  (103/L) 1160.6 ± 123.6 1134.5 ± 192.4 1131.7 ± 109.5 1173.5 ± 143.1 1042.8 ± 232.3 1053.9 ± 136.3 1122.2 ± 138.3 1115.7 ± 113.8
NEUT  (%) 21.72 ± 6.06 25.32 ± 8.43 23.52 ± 8.04 19.30 ± 5.33 11.90 ± 3.68 14.47 ± 7.50 14.06 ± 6.46 15.44 ± 6.29
LYMPH (%) 73.18 ± 6.78 69.93 ± 8.73 71.79 ± 8.50 76.32 ± 5.37 84.38 ± 4.43 81.46 ± 7.81 81.98 ± 6.87 80.30 ± 6.90
MONO (%) 4.76 ± 1.23 4.41 ± 0.70 4.37 ± 1.03 4.00 ± 1.17 3.46 ± 1.18 3.70 ± 0.87 3.68 ± 0.64 3.92 ± 1.27
EOSIN  (%) 0.28 ± 0.15 0.30 ± 3.39 0.29 ± 0.16 0.32 ± 0.28 0.27 ± 0.26 0.33 ± 0.21 0.28 ± 0.27 0.34 ± 0.24
BASO  (%) 0.06 ± 0.07 0.05 ± 0.05 0.03 ± 0.05 0.07 ± 0.05 0.00 ± 0.00 0.04 ± 0.09 0.01 ± 0.03 0.00 ± 0.00
PT  (sec) 12.12 ± 1.92 12.84 ± 1.74 13.78 ± 2.03 13.31 1.91 9.26 0.22 9.23 ± 0.26 9.07 ± 0.16 9.28 ± 0.21
APTT  (sec) 16.97 ± 1.12 15.68 ± 2.58 17.13 ± 2.27 17.09 0.88 14.61 0.70 14.82 ± 0.67 14.99 ± 0.65 14.10 ± 0.83
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orpuscular hemoglobin concentration; PLT: platelet; NEUT: neutrophil; LYMPH:
PTT:  activated thromboplastin time.
n mice using an in vivo micronucleus test. All test animals were
ivided into ﬁve groups which received negative control (sterile
ater), positive control (80 mg/kg b.w cyclophosphamide), or LDAC
t dose levels of 700, 1400 or 2800 mg/kg b.w. After 96 h post-
reatment, no mortalities were recorded, and gross necropsy of the
nimals revealed no macroscopic ﬁndings. The mean body weight
as analyzed with t-test showed no signiﬁcant difference between
hree doses of LDAC and control groups in both genders (Table S3).
The percentage of PCE and micronucleus frequency were ana-
yzed 48 and 72 h post- treatment of control and test sample
Table 5). The percentage of positive control groups at 48 h were
.60 ± 0.36% in female and 1.02 ± 0.19% in male. The percent-
ge of PCE in positive control was signiﬁcantly decreased after
osing, which indicates that cyclophosphamide inhibits erythro-emoglobin; HCT: hematocrit; MCV: mean corpuscular hemoglobin; MCHC: mean
hocyte; MONO: monocyte; EOSIN: eosinophil; BASO: basophil; PT: prothrombin;
poiesis. However, the percentage of PCE in LDAC treated groups
showed no signiﬁcant decrease than negative control group, sug-
gest that all the testing doses of LDAC did not affect erythropoiesis.
We further examined the micronucleus frequency in 1000 PCE
using ﬂuorescence microscope and the data was summarized in
Table 5. The micronucleus frequency in 1000 PCE of negative con-
trol group at 48 and 72 h were 0.17 ± 0.26 and 0.42 ± 0.38 ‰PCE in
female, 0.67 ± 0.68 and 0.50 ± 0.63 ‰PCE in male, respectively. The
micronucleus frequency of 1000 PCE of positive control group at
48 h were 23.80 ± 12.09 in female and 28.80 ± 5.62 ‰PCE in male.
After statistical analysis with Poisson distribution methods, there
was no signiﬁcant difference between three testing doses of LDAC
and negative control group in both genders at 48 and 72 h. Based on
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Table  8
Effect of repeated oral dose (90 days) of LDAC on rats: Serum chemical analysis.
Serum chemistry (Mean ± S.D, n = 12)
Parameters Male Female
LDAC (mg/kg b.w) LDAC (mg/kg b.w)
Control (WFI) 700 1400 2800 Control (WFI) 700 1400 2800
AST (U/L) 104.30 ± 13.64 110.31 ± 18.18 98.04 16.71 116.13 ± 63.04 93.74 ± 29.50 91.54 ± 18.42 81.88 ± 15.46 82.13 ± 12.5
ALT  (U/L) 29.41 ± 4.59 32.92 ± 6.04 30.78 8.47 46.33 ± 55.03 22.08 ± 6.16 20.53 ± 4.13 21.22 ± 6.22 20.72 ± 4.91
Glucose (mg/dL) 165.17 ± 12.47 163.43 ± 20.90 166.86 30.76 201.56 ± 31.73* 161.35 ± 36.04 166.30 ± 43.11 165.14 ± 17.37 162.23 ± 30.09
TP  (g/dL) 6.49 ± 0.23 6.36 ± 0.29 6.26 0.20* 6.39 ± 0.21 6.54 ± 0.35 6.62 ± 0.41 6.80 ± 0.31 6.78 ± 0.48
ALB  (g/dL) 4.10 ± 0.10 4.16 ± 0.16 4.07 0.15 4.15 ± 0.25 4.58 ± 0.28 4.57 ± ± 0.29 4.83 ± 0.38 4.83 ± 0.47
TBIL  (mg/dL) <0.070 <0.050 <0.04 <0.04 <0.068 ± 0.02 <0.05 ± 0.00 <0.06 ± 0.02 <0.06 ± 0.0
BUN  (mg/dL) 14.07 ± 1.60 14.26 ± 1.91 14.02 1.72 13.93 ± 1.84 16.08 ± 2.34 16.08 ± 1.35 16.79 ± 1.90 15.53 ± 2.47
CR  (mg/dL) 0.48 ± 0.05 0.50 ± 0.07 0.48 0.07 0.48 ± 0.08 0.59 ± 0.10 0.60 ± 0.09 0.57 ± 0.07 0.57 ± 0.07
GGT  (U/L) <2.0 <2.0 <2.0 <2.0 <2.9 <2.0 <2.20 <2.0
ALP  (U/L) 268.28 ± 39.73 251.16 ± 51.25 243.00 40.77 264.99 ± 47.89 135.99 ± 23.79 141.18 ± 34.11 114.79 ± 34.15 117.93 ± 24.24
CHL  (mg/dL) 59.70 ± 22.37 66.28 ± 13.77 62.73 13.131 67.99 ± 15.28 66.74 ± 12.57 73.84 ± 11.69 90.07 ± 18.41* 91.24 ± 15.67*
TG  (mg/dL) 21.94 ± 7.07 25.58 ± 12.23 24.38 6.13 25.23 ± 9.18 23.71 ± 4.80 24.73 ± 13.66 29.13 ± 9.31 24.78 ± 14.54
Ca  (mg/dL) 10.13 ± 0.25 10.23 ± 0.48 10.12 0.28 10.27 ± 0.37 10.13 ± 0.48 9.91 ± 0.27 10.26 ± 0.27 10.13 ± 0.37
P  (mg/dL) 6.75 ± 0.48 7.13 ± 0.67 6.74 0.30 6.88 ± 0.46 5.73 ± 0.47 5.68 ± 0.89 5.64 ± 0.67 5.48 ± 0.58
CRK  (U/L) 501.64 ± 222.60 533.35 ± 185.87422.52 110.53 514.47 ± 258.65432.54 ± 157.35 506.48 ± 224.51 379.34 ± 175.39363.27 ± 183.51
Am  (U/L) 11394.1 ± 178.4 1380.8 ± 262.9 1450.3 164.8 1674.5 ± 250.0 1019.6 ± 176.1 993.2 ± 187.3 1119.3 ± 233.2 1080.4 ± 242.2
Na  (mM) 147.22 ± 1.75 148.24 ± 3.88 147.68 1.44 147.28 ± 1.53 143.84 ± 0.85 143.42 ± 1.46 144.08 ± 1.27 144.56 ± 0.86
K  (mM)  4.508 ± 0.147 4.510 ± 0.253 4.624 0.25 4.75 ± 0.28 4.05 ± 0.19 4.11 ± 0.30 4.20 ± 0.22 4.22 ± 0.23
Cl  (mM)  109.39 ± 2.31 108.02 ± 2.97 108.00 1.60 107.43 ± 1.02 106.62 ± 1.14 106.05 ± 2.05 106.63 ± 1.53 106.04 ± 1.82
*Statistically signiﬁcant from LDACC treatment group vs. negative control group. AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; TP: total protein; ALB:
albumin; TBIL: total bilirubin; BUN: blood urea nitrogen; GGT: gamma-glutamyl transferees; CHL: cholesterol; ALP: alkaline phosphatase; TG: triglyceride; Ca: calcium; P:
phosphorus; CRK: creatinine kinase; Am: amylase; Na: Sodium; K: potassium; Cl: chloride.
Table 9
Effect of repeated oral dose (90 days) of LDAC on rats: Internal organ weight.
Organ weight (Mean ± S.D, n = 12)
Organs Male Female
LDAC (mg/kg b.w) LDAC (mg/kg b.w)
Control (WFI) 700 1400 2800 Organs Control (WFI) 700 1400 2800
Adrenals 0.05 ± 0.00 0.05 ± 0.00 0.05 ± 0.00 0.05 ± 0.00 Adrenals 0.11 ± 0.15 0 .06 ± 0.00 0.07 ± 0.00 0.08 ± 0.00
Pituitary 0.012 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 Pituitary 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00
Brain  2.06 ± 0.12 2.09 ± 0.03 2.08 ± 0.09 2.09 ± 0.16 Ovaries 0.12 ± 0.01 0.12 ± 0.01 0.12 ± 0.02 0.12 ± 0.01
Epididymides 1.31 ± 0.11 1.42 ± 0.15 1.31 ± 0.08 1.38 ± 0.17 Brain 1.95 ± 0.10 1.95 ± 0.09 1.98 ± 0.05 1.96 ± 0.10
Heart  1.53 ± 0.13 1.45 ± 0.11 1.50 ± 0.13 1.57 ± 1.14 Heart 0.96 ± 0.06 0.94 ± 0.06 0.97 ± 0.05 0.98 ± 0.05
Kidneys 3.24 ± 0.35 3.32 ± 0.33 3.34 ± 0.49 3.50 ± 0.26 Kidneys 1.91 ± 0.16 1.92 ± 0.18 2.02 ± 0.27 2.10 ± 0.28
Liver  13.18 ± 1.36 13.63 ± 1.63 14.02 ± 1.47 16.01 ± 1.76* Liver 8.13 ± 2.27 7.95 ± 0.71 8.47 ± 0.57 8.49 ± 0.91
Spleen  0.81 ± 0.15 0.83 ± 0.09 0.83 ± 0.10 0.82 ± 0.14 Spleen 0.56 ± 0.20 0.51 ± 0.10 0.54 ± 0.07 0.54 ± 0.10
Testes  3.07 ± 0.23 3.37 ± 0.33 3.21 ± 0.19 3.21 ± 0. 18* Thymus 0.30 ± 0.05 0.31 ± 0.06 0.31 ± 0.07 0.32 ± 0.06
Thymus 0.40 ± 0.09 0.36 ± 0.10 0.37 ± 0.11 0.41 ± 0.09 Uterus with cervix 0.70 ± 0.23 0.75 ± 0.27 ± 0.63 0.16 0.79 ± 0.31
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Statistically signiﬁcant (p < 0.05) from LDACC treatment group vs. vehicle control g
hese observations, we conclude that all the testing doses of LDAC
oes not increase micronucleated PCE in the test condition.
.4. Acute (14-day) oral toxicology study
Exposure of animals to the tested doses of LDAC (1400, 2800 and
600 mg/kg b.w) produced neither deaths nor treatment-related
igns of toxicity in any of the treatment groups during the study.
n addition, no weight loss resulted from the LDAC treatment com-
are to the control groups in both genders after 1, 4, 8 and 15 days.
ata of individual animal body weight and mean body weight are
ummarized in Table S4. Moreover, there were no abnormal clini-
al ﬁndings from external observations which were attributable to
DAC treatment. However, animals in Group IV showed slight hair
oss during the study, which may  be caused by the animal ﬁghtings
hich was not related to the LDAC treatment. Furthermore, there
ere no abnormal ﬁndings from the gross pathological examina-
ion of internal organs including thoracic and abdominal cavities,
ntestines, or visceral organs at necropsy in all groups of animals.PSVCG: prostates and seminal vesicles with coagulating glands.
Based on these results, the oral LD50 of LDAC is found to be greater
than 5 g/kg b.w for both genders. Data generated from this study
provide safety information for human exposure and also provide
information to establish a dose regimen in further studies.
3.5. Repeated dose (90 days) oral toxicity study
The repeated oral dose (90 days) toxicity study showed that
there no mortalities or ophthalmologic and treatment related signs
of toxicity were observed during the study period in any of the
treatment groups (Table S5). No statistically signiﬁcant mean body
weight and mean body weight gain in both genders were reported
between the test and control groups (Table S6 and S7 respectively).
In addition, there were no statistically signiﬁcant variations in food
consumption in all test groups (data not presented). Moreover, no
treatment related severe clinical signs were observed in all test ani-
mals throughout the study period (Table 6). However, some clinical
signs were observed due to housing behavior (wounds) or individ-
ual animal differences (hair loss). In male rats, wound and hair loss
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Table 10
Effect of LDAC on fetal development.
LDAC (mg/kg)
Control 700 1400 2800
Fetal body weight (g) 4.10 ± 0.37 4.24 ± 0.20 4.29 ± 0.24 4.32 ± 0.42
Fetal  body length (mm)  36.34 ± 1.77 36.47 ± 1.44 37.13 ± 1.52 37.03 ± 2.04
Total  examined number 371 358 307 363
External examination number 371 358 307 363
Visceral examination number 181 172 149 173
Skeletal examination number 190 186 158 190
External examination (%)
Craniorachischisis 0.00 ± 0.00 0.00 ± 0.00 0.30 ± 1.43 0.00 ± 0.00
Exencephaly 0.00 ± 0.00 0.00 ± 0.00 0.30 ± 1.43 0.00 ± 0.00
Open  eyelid 0.00 ± 0.00 0.00 ± 0.00 0.30 ± 1.43 0.00 ± 0.00
Visceral examination (%)
Brain irregular shape 0.00 ± 0.00 0.00 ± 0.00 0.65 ± 3.05 0.00 ± 0.00
Cerebral ventricular ellargement 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.53 ± 2.75
Asplenia 0.00 ± 0.00 0.00 ± 0.00 0.65 ± 3.05 0.00 ± 0.00
Diaphragmatic hernia 0.55 ± 2.80 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
Distended renal pelvis 1.10 ± 3.89 0.00 ± 0.00 0.00 ± 0.00 0.53 ± 2.75
Hydroureters 0.55 ± 2.80 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
Ureter distended 0.48 ± 2.45 1.81 ± 6.50 0.00 ± 0.00 0.00 ± 0.00
Skeletal examination (%)
Hyoid, not ossiﬁed or incompletely oosiﬁed 0.00 ± 0.00 0.50 ± 2.50 0.00 ± 0.00 0.46 ± 2.41
Sternbrae, misaligned 1.10 ± 3.89 2.00 ± 10.00 1.64 ± 5.73 0.00 ± 0.00
Sternbrae, one or more not ossiﬁed 18.55 ± 22.33 6.96 ± 11.22 9.45 ± 16.71 9.47 ± 14.74
Strenbrae, one or more incompletely ossiﬁed 18.99 ± 22.99 18.00 ± 20.40 12.01 ± 15.70 21.62 ± 26.28
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ere observed one in 12 rats of vehicle control group. In female rats,
ound was observed in 1 in 12 rats of highest LDAC (2800 mg/kg)
reated group, and hair loss was found in one in 12 rats of 700 mg/kg
DAC treated group and two in 12 rats of 2800 mg/kg treated group
Table 6).
There were no statistically signiﬁcant differences were observed
rom the results of hematological parameters of male rats, whereas
ome statistically signiﬁcant differences were observed in female
ats treated with LDAC. Particularly, the hematocrit of the high-
ose group (2800 mg/kg) was statistically (p < 0.05) lower than that
f vehicle control group (Table 7). Results from individual animal
erum chemistry analysis showed some statistically signiﬁcant dif-
erences in both genders as summarized in Table 8. In male rats,
he glucose levels in high-dose (2800 mg/kg) treated group was
tatistically higher than that of control group. The total protein
evel in the 1400 mg/kg/day LDAC treated group was  signiﬁcantly
ower than vehicle control group. In female rats, compared to vehi-
le control group a signiﬁcant increase of total cholesterol in 1400
nd 2800 mg/kg treatment groups. However, there was  no statis-
ically signiﬁcant difference in triglyceride levels. Urine analysis
howed there was no signiﬁcant difference in volume, speciﬁc
ravity and urobilinogen in all tested groups, whereas the pH of
igh-dose (2800 mg/kg) treated rats were statistically lower than
ehicle control group in both genders (Table S8). However, despite
hose statistical differences, the data were within the normal his-
orical range and without physiological abnormalities.
The internal organ weights in all treated groups of both genders
ere not signiﬁcantly different from those of the vehicle con-
rol groups with the exception of the liver weight of those male
nimals in the highest dose (2800 mg/kg) group (Table 9). This
ifference between control (13.18 ± 1.36 g) and high-dose treat-
ent group included the increased weight after 90 days in male
16.01 ± 1.76 g). This statistical difference was within normal his-
orical control range and without physiological abnormalities. In
emales, there was no statistical difference between the vehicle
ontrol and LDAC treated groups (Table 9).
Moreover, results of gross necropsy ﬁndings revealed that there
ere neither signs of toxicity noted with respect to gross exam-2.72 ± 8.24 4.14 ± 7.16 2.16 ± 7.59 1.46 ± 5.45
8.43 ± 14.66 8.54 ± 13.50 7.66 ± 10.46 8.81 ± 14.15
9.46 ± 15.44 9.53 ± 17.12 4.8410.39 2.93 ± 6.59
ination of all organs examined (Table S9). However, one female
animal of vehicle control group was observed to have bone marrow
cavity discoloration in the femur, moderate enlargement of spleen
and liver. Histopathologically, myeloid hyperplasia of mononuclear
cells was noted in the liver, spleen and bone marrow in femur. All
lesions showed moderate mononuclear cell leukemia. According
to the severity and incidence in histopathological evaluation, this
lesion was  considered to be a spontaneous abnormality and not
related to the LDAC exposure (Table S10).
3.6. Reproductive and developmental toxicity assessment
After co-habitation of male and female animals over-night,
impregnation was  veriﬁed each morning by detection of the vagi-
nal plug in vagina or on cage board or the presence of spermatozoa
by vaginal smear. The vaginal smear was performed in animals
without vaginal plug. The numbers of animals with impregnation
veriﬁed in the control and groups given 700, 1400 or 2800 mg/kg
b.w. during the study period were 26/29, 25/28, 22/28 and 27/29,
respectively. The pregnant animal numbers veriﬁed at necropsy in
the control and 700, 1400 and 2800 mg/kg LDAC treatment groups
were 26, 25, 22 and 27, respectively. The conﬁrmed pregnancy rats
were high (80–90%) for all groups. There was no maternal mortal-
ity or moribundity found in this study. The maternal body weight
was measured in gestation period (G0, G3, G6, G9, G12, G15, G18,
G20 and G20 without uterus weight). There was  no statistically
signiﬁcant maternal body weight and weight gain among the study
groups (data not presented). Maternal food and water consumption
showed no consistent dose-related differences during the study
period (data not presented).
Clinical observation was  performed once daily during gesta-
tion period (G0–G20). Slight to moderate hair loss was  observed
at various sites in vehicle control, 700 and 1400 mg/kg LDAC treat-
ment groups with the incidence of 2/26, 1/25 and 2/22, respectively
Table S11 This clinical sign was considered to be caused by nesting
behavior and is commonly observed in pregnant animals and so not
related to LDAC administration.
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[15] M.S. Zhang, I.S. Bang, C.B. Park, Lack of mutagenicity potential of PeriplocaC.-C. Lin et al. / Toxicolog
Results of maternal evaluation showed that there were no statis-
ical signiﬁcant differences between the groups observed in gravid
terus weight, implantation number, corpora lutea number, lit-
er size, live or dead fetal number, male or female fetus number,
esorption number, fetal sex ratio (M/F), pre-implantation loss and
ost-implantation loss (Table S12).
Results from fetal examination showed that there was  no sta-
istical signiﬁcance noted in fetal body weight and body length
mong the test groups. However, in the gross examination of the
etal appearance, one fetus from 1400 mg/kg LDAC treatment group
howed craniorachischisis, exencephaly and open eyelid (Table 10).
his ﬁnding meet the prevalence with low incidences in normal
D rat population. Fifty percent of each litter were allocated to
isceral examination (Table 10). There was no dose response sig-
iﬁcance noted in the incidence of abnormalities. The observed
bnormalities included irregular shape of brain, cerebral ven-
ricular enlargement, asplenia, diaphragmatic hernia, distended
enal pelvis, hydroureters and distended ureter. However, the inci-
ences were low and all within historical reference range. Skeletal
xamination of 50% fetuses of each litter was  performed with
lizarin Red S and Alcian Blue staining. LDAC treatment showed
o statistically signiﬁcant incidences or abnormalities in tested
etuses. The fetal skeletal examination suggest that there was  no
DAC (700–2800 mg/kg) treatment related abnormalities and LDAC
elated teratogenic toxicity. These data are well correlated with a
revious study which reports that the mycelial extract of A. cin-
amomea (50–500 mg/kg b.w) does not showed any teratogenic
ffects in female SD rats [4]. However, the highest oral dose of the
resent study was 5-fold higher than the previous report.
. Conclusion
LDAC showed no mutagenic activity in the bacterial reverse
utation test, did not induce micronuclei in mammalian erythro-
ytes or increase the rates of structural and numerical chromosome
berration of CD mice. The results of acute (14 days) and repeated
90 days) oral toxicity studies of LDAC in rats (LD50 is greater than
 g/kg b.w and there was no evident toxicity at 2800 mg/kg/day)
onﬁrm in part, safety of LDAC for oral consumption. Based on the
esults of reproductive and developmental toxicity study, there
ere no observable segment II reproductive and developmental
vidences of LDAC. The no observable adverse effect dose level
NOAEL) under the conditions of this study was  2800 mg/kg. Taken
ogether, the present studies demonstrate that LDAC has a very
ow order of toxicity, which supports the safety of LDAC for human
onsumption.rts 2 (2015) 1409–1417 1417
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.toxrep.2015.10.
007.
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